Latest news
Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) has accepted the first-ever Biol...
Amsterdam, The Netherlands, 14th of July 2022 Polpharma Biologics, an international biotech company dedicated to the development of biosimilars, announced today that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for biosimilar natalizumab, a proposed biosimilar to Tysabri®*. The application is for an intravenous (IV) route of administration,...
MHRA’s authorization for BIOEQ’s biosimilar in the United Kingdom.
We are pleased to share last week’s news on the approval of the marketing authorization application of BIOEQ’s Lucent...
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "we...
Zug, Switzerland – MS Pharma has signed an exclusive licensing and supply agreement with Bioeq AG, Switzerland, the P...
Bioeq has received notification by the U.S. Food and Drug Administration (FDA) that the biologics license application...
The new roles come on top of significant growth at the company in the last two years, with an additional 300 employee...
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has...
Our attention has been drawn to the fraudulent activities of persons posing as recruitment agencies or Polpharma Biol...